Drug firm Bharat Parenterals on Saturday said it has received approval from the Drugs Controller General of India (DCGI) for favipiravir oral suspension, to be used for treatment of COVID-19 patients.
The company has received licence and authorisation from DCGI to manufacture and market favipiravir oral suspension l00mg/ml, Bharat Parenterals said in a regulatory filing.
Favipiravir, an antiviral drug, was approved in Japan in 2014 for the treatment of novel or re-emerging influenza virus infections.
Amruta Fadnavis Fires Back At Ex-Maharashtra CM Prithviraj Chavan’s 'Marathi PM' Claim: 'Best Of Luck To Him'
Disha Salian Death Case: 5 Years On, Investigation Still Delayed Amid Political Claims And Ongoing Legal Challenges
Disha Salian Death Case: Bombay HC Seeks Medical Reports Before Considering Plea For FIR; State Awaiting Fresh Forensic Findings
Bombay HC Questions ‘Malafide’ In Scaling Down Zeeshan Siddique’s Security After Father Baba Siddique’s Murder; Seeks Committee Records
